Xenotransplantation: The Progress of Pig-to-Human Heart Transplants

Early 2022 marked a pivotal milestone in transplant medicine when researchers from the University of Maryland Medical School successfully transplanted a gene-edited pig heart into a human patient. This breakthrough represented the culmination of more than 20 years of dedicated research in xenotransplantation, a field that had struggled to move beyond experimental stages for decades. For many years, only a few international research groups kept xenotransplantation research alive, and the successful clinical transplant validated their decades of persistence and innovation.

The significance of this achievement cannot be overstated. The transplant patient survived longer than the first recipient of a traditional human-to-human heart transplant, demonstrating that xenotransplantation could potentially offer viable therapeutic benefits. This success was enabled by Revivicor's gene-edited pig heart, which had undergone multiple genetic modifications to improve compatibility with the human immune system and address physiological differences between species.

Xenotransplantation faces multiple biological hurdles, and CRISPR technology addresses them systematically through precise genetic modifications. The primary barrier involves xenoantigens—pig proteins that trigger immediate rejection by the human immune system. By using CRISPR to target and modify or eliminate porcine genes encoding these xenoantigens, researchers can dramatically reduce the transplanted organ's immunogenicity.

Beyond immunological compatibility, researchers must overcome physiological incompatibilities. Pigs and humans have different coagulation systems and other physiological parameters that must be harmonized for successful transplantation. Modern xenotransplant designs include six added human genes to improve immune acceptance and four inactivated porcine genes to reduce rejection risk and moderate organ growth. This multi-gene approach represents a significant advancement from earlier attempts that focused on single genetic modifications.

One unexpected challenge in xenotransplantation is the size mismatch between pigs and human recipients. Standard commercial pigs weigh approximately 115 kilograms when slaughtered, but can grow up to 400 kilograms, making their organs too large for most adult humans. Researchers addressed this problem through innovative genetic engineering, specifically by knocking out the gene encoding the growth hormone receptor.

By disabling this growth gene, scientists can produce pigs that reach only 75-100 kilograms—comparable to average adult humans. This genetic modification is crucial because it allows researchers to use organs from fully mature, physiologically developed pigs rather than younger animals whose organ function may not be optimal. This approach was implemented in the recent heart xenotransplantation, representing one of the best technical solutions available for ensuring organ compatibility and maturity.

Following the success of the initial heart transplant, the field has rapidly expanded to include kidney xenotransplants and systematic clinical trials. NYU Langone Health initiated the EXPAND study, testing a gene-edited pig kidney with 10 genetic modifications known as the UKidney. This kidney-focused trial represents the first-of-its-kind systematic evaluation of xenokidney transplantation in living recipients rather than just neurologically deceased donors.

The EXPAND study offers particular hope to the thousands of Americans waiting for kidney transplants, many of whom face death or permanent dialysis dependency before human organs become available. Early data from various xenotransplant procedures at NYU Langone shows mixed but encouraging results, with some recipients achieving extended organ survival and improved quality of life, though complications such as infections and organ removal have also occurred in some cases requiring ongoing monitoring and refinement.

While xenotransplantation has achieved clinical proof-of-concept, widespread adoption requires meeting several critical conditions. Experts estimate that widespread clinical use could occur within 5-10 years, though this timeline depends on multiple factors including long-term safety validation and regulatory approvals. One essential requirement is FDA approval of immunosuppressive medications specifically designed to support xenotransplant recipients; the initial heart transplant used an experimental immunosuppressive drug whose approval status remains uncertain.

Beyond regulatory pathways, the field must address infrastructure and training challenges. Pig production must scale significantly to supply enough organs for thousands of potential recipients annually, and transplant centers worldwide must develop expertise in xenotransplant procedures. In response to these needs, the International Society for Heart and Lung Transplantation released the 2026 ISHLT Consensus Statement on Clinical Cardiac Xenotransplantation, establishing comprehensive standards for preclinical evidence, patient selection, genetic engineering requirements, surgical technique, immunosuppression, and infection surveillance to guide disciplined expansion of the field.